The use of psychotropic medicatioins in eating disorder patients with personality disorders

Eating Disorders

Volumn 13, Issue 1, 2005, Pages 123-134

  Sansone, Randy A ^a,b,d   Sansone, Lori A ^c  

^a WRIGHT STATE UNIVERSITY   (United States)

^b KETTERING MEDICAL CENTER   (United States)

^c Premier Health Network   (United States)

^d Sycamore Primary Care Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE DERIVATIVE; BUSPIRONE; CARBAMAZEPINE; CITALOPRAM; CLOZAPINE; ESCITALOPRAM; FLUOXETINE; GABAPENTIN; LITHIUM; NEUROLEPTIC AGENT; OLANZAPINE; OPIATE ANTAGONIST; PAROXETINE; PSYCHOTROPIC AGENT; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TOPIRAMATE; TRICYCLIC ANTIDEPRESSANT AGENT; VALPROATE SEMISODIUM; VENLAFAXINE; ZIPRASIDONE;

BORDERLINE STATE; BULIMIA; CLINICAL TRIAL; COMORBIDITY; DRUG EXCRETION; DRUG PREFERENCE; DRUG RESEARCH; DRUG USE; EATING DISORDER; HUMAN; PATIENT SELECTION; PERSONALITY; PERSONALITY DISORDER; PHILOSOPHY; PRESCRIPTION; PSYCHOLOGICAL THEORY; REVIEW; SYMPTOMATOLOGY; TREATMENT PLANNING;

EID: 12744279654     PISSN: 10640266     EISSN: None     Source Type: Journal    
DOI: 10.1080/10640260590893728     Document Type: Review

References (44)

1. American Psychiatric Association. (1994). Diagnostic and statistical manual of mental disorders (4th ed). Washington, DC: Author.
2. American Psychiatric Association. (2000). Practice guidelines for the treatment of patients with eating disorders (revision Washington, DC: Author.
3. American Psychiatric Association. (2001). Practice guidelines for the treatment of patients with borderline personality disorder. American Journal of Psychiatry, 158, S1-52.
4. Bagby, R. M., Ryder, A. G., & Cristi, D. (2002). Psychosocial and clinical predictors of response to pharmacotherapy for depression. Journal of Psychiatry & Neuroscience, 27, 250-257.
5. Black, K. J., & Sheline, Y. I. (1997). Personality disorder scores improve with effective pharmacotherapy of depression. Journal of Affective Disorders, 43, 11-18.
6. Brewerton, T. D. (1999). Binge eating disorder: Diagnosis and treatment options. CNS Drugs, 11, 351-361.
7. Brinkley, J. R. (1993). Pharmacotherapy of borderline states. Psychiatric Clinics of North America, 16, 853-884.
8. Chick, D., Martin, S. K., Nevels, R., & Cotton, C. R. (1994). Relationship between personality disorders and clinical symptoms in psychiatric inpatients as measured by the Millon Clinical Multiaxial Inventory. Psychological Reports, 74, 331-336.
9. Coccaro, E. F. (1993). Psychopharmacological studies in patients with personality disorders. Journal of Personality Disorders Supplement 1, 181-192.
10. Coccaro, E. F. (1998). Clinical outcome of psychopharmacologic treatment of borderline and schizotypal personality disordered subjects. Journal of Clinical Psychiatry, 59, 30-35.
11. Demetriou, A. (2003). Mind, self, and personality: Dynamic interactions from late childhood to early adulthood. Journal of Adult Development, 10, 151-171.
12. Ellison, J. M., & Shader, R. I. (2003). Pharmacologic treatment of personality disorders: A dimensional approach. In R. I. Shader (Ed.), Manual of psychiatric therapeutics (pp. 169-183). Philadelphia: Lippincott, Williams, & Wilkins.
13. Ewing, S. E., Falk, W. E., & Otto, M. W. (1996). The recalcitrant patient: Treating disorders of personality. In M. H. Pollack, M. W. Otto, & J. F. Rosenbaum (Eds.), Challenges in clinical practice: Pharmacologic and psychosocial strategies (pp. 355-379). New York: Guilford.
14. Friis, S., Wilberg, T., Dammen, T., & Urnes, O. (1999). Pharmacotherapy for patients with personality disorders: Experiences from a group analytic treatment program. In J. Derksen & C. Maffei (Eds.), Treatment of personality disorders (pp. 255-268). Netherlands: Kluwer.
15. Gardner, D. L., & Cowdry, R. W. (1986). Positive effects of carbamazepine on behavioral dyscontrol in borderline personality disorder. American Journal of Psychiatry, 143, 519-522.
16. Gillig, P. M. (2000). Integration of psychotherapy and medication in the treatment of severe personality disorders. In L. VandeCreek (Ed.), Innovations in clinical practice: A source book (pp. 73-84). Sarasota, FL: Professional Resource Press.
17. Gitlin, M. J. (1993). Pharmacotherapy of personality disorders: Conceptual framework and clinical strategies. Journal of Clinical Psychopharmacology, 13, 343-353.
18. Grossman, R. (2002). Psychopharmacologic treatment of patients with borderline personality disorder. Psychiatric Annals, 32 357-370.
19. Hyler, S. E. (1994). The Personality Diagnostic Questionnaire-4 (PDQ-4). New York State Psychiatric Institute: Author.
20. Kapfhammer, H. P., & Hippius, H. (1998). Special feature: Pharmacotherapy in personality disorders. Journal of Personality Disorders, 12, 277-288.
21. Kavoussi, R., & Coccaro, E. F. (1999). Pharmacotherapy. In M. Hersen, & A. S. Bellack (Eds.), Handbook of comparative interventions for adult disorders (2nd ed., pp. 584-600). New York: John Wiley & Sons.
22. Koenigsberg, H. W., Woo-Ming, A. M., & Siever, L. J. (2002). Pharmacological treatments for personality disorders. In P. E. Nathan, & J. M. Gorman (Eds.), A guide to treatments that work (pp. 625-641). London: Oxford Press.
23. Markovitz, P. (2001). Pharmacotherapy. In W. J. Livesley (Ed.), Handbook of personality disorders: Theory, research, and treatment (pp. 475-493). New York: Guilford.
24. Marx, R., Kotwal, R., McElroy, S. L., & Malhotra, S. (2003). What treatment data support topiramate in bulimia nervosa and binge eating disorder? What is the drug's safety profile? How is it used in these conditions? Eating Disorders: The Journal of Treatment and Prevention, 11, 71-75.
25. Millon, T., Davis, R., & Millon, C. (1997). Millon Clinical Multiaxial Inventory-III Manual (2nd ed.). Minneapolis, MN: National Computer Systems.
26. Moleman, P., van Dam, K., & Dings, V. (1999). Psychopharmacological treatment of personality disorders: A review. In J. Derkson, & C. Maffei (Eds.), Treatment of personality disorders (pp. 207-227). Netherlands: Kluwer.
27. Peterson, C. B., & Mitchell, J. E. (1999). Psychosocial and pharmacological treatment of eating disorders: A review of research findings. Journal of Clinical Psychology, 55, 685-697.
28. Powers, P. S. (2000). Psychopharmacological approaches to eating disorders. Academy for Eating Disorders Newsletter, 16, 2, 7.
29. Rivas-Vazquez, R. A., & Blais, M. A. (2002). Pharmacologic treatment of personality disorders. Professional Psychology: Research and Practice, 33, 104-107.
30. Sansone, R. A., Gentile, J., & Markert, R. J. (2000). Drug allergies among patients with borderline personality disorder. General Hospital Psychiatry, 22, 289-293.
31. Sansone, R. A., Levitt, J. L., & Sansone, L. A. (2005). Psychotropic medications, selfharm behavior, and eating disorders. In J. L. Levitt, R. A. Sansone, & L. Cohn (Eds.), Self-harm behavior and eating disorders: Dynamics, assessment, and treatment. New York: Brunner Routledge.
32. Sansone, R. A., Levitt, J. L., & Sansone, L. A. (2005). The prevalence of personality personality disorders among those with eating disorders. Eating Disorders: The Journal of Treatment & Prevention, 13 1):7-21.
33. Sansone, R. A., Rytwinski, D. R., & Gaither, G. A. (2003). Borderline personality and psychotropic medication prescription in an outpatient psychiatry clinic. Comprehensive Psychiatry, 44, 454-458.
34. Siever, L. J., Koenigsberg, H. W., & Reynolds, D. (2003). Neurobiology of personality disorders: Implications for a neurodevelopmental model. In D. Cicchetti, & E. Walker (Eds.), Neurodevelopmental mechanisms in psychopathology (pp. 405-427). New York: Cambridge University Press.
35. Silk, K. R. (1999). Collaborative treatment for patients with personality disorders. In R. B. Riba, & R. Balon (Eds.), Psychopharmacology and psychotherapy: A collaborative approach (pp. 221-277). Washington, DC: American Psychiatric Press.
36. Soloff, P. H. (1994). Is there any drug treatment of choice for the borderline patient? Acta Psychiatrica Scandinavica, 89, 50-55.
37. Soloff, P. H. (1998). Algorithms for pharmacological treatment of personality dimensions: Symptom-specific treatments for cognitive-perceptual, affective, and impulsive-behavioral dysregulation. Bulletin of the Meninger Clinic, 62, 195-214.
38. Soloff, P. H. (2000). Psychopharmacology of borderline personality disorder. Psychiatric Clinics of North America, 23, 169-192.
39. Spitz, R. T. (1999). Treatment noncompliance among hospitalized forensic patients. Dissertation Abstracts International, 60, 815.
40. Spitzer, R. L., Williams, J. B. W., Gibbon, M., & First, M. B. (1990). Structured Clinical Interview for DSH-III-R Personality Disorders (SCID-II). Washington, DC: American Psychiatric Press.
41. Trestman, R. L., Woo-Ming, A. M., de Vegvar, M., & Siever, L. J. (2001). Treatment of personality disorders. In A. F. Schatzberg, & C. B. Nemeroff (Eds.), Essentials of clinical psychopharmacology (pp. 571-587). Washington, DC: American Psychiatric Publishing.
42. Uzuncan, T. A. (2003). The maternal environment: Facilitating the emotional foundations of the mind. Dissertation Abstracts International, Section B, 64, 1528.
43. Zanarini, M. C., Frankenburg, F. R., Dubo, E. D., Sickel, A. E., Trikha, A., Levin, A., et al. (1998). Axis I comorbidity of borderline personality disorder. American Journal of Psychiatry, 155 1733-1739.
44. Zimmerman, M., & Mattia, J. I. (1999). Axis I diagnostic comorbidity and borderline personality disorder. Comprehensive Psychiatry, 40, 245-252.